Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.54 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 1/20 | 0.40 |
| ▸ | TGM2 | P21980 | 2/20 | 0.39 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.39 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389169 | 1.00 | ITGB3 (0.54) | ITGB3ITGA2BHDAC1TSHRHDAC4 | |
| SCHEMBL4911413 | 0.97 | ITGB3 (0.50) | ITGB3ITGA2BHDAC1TSHRHDAC4 | |
| SCHEMBL6390296 | 0.91 | ITGB3 (0.55) | ITGB3ITGA2BHDAC1TSHRHDAC4 | |
| SCHEMBL6392307 | 0.91 | ITGB3 (0.55) | ITGB3ITGA2BHDAC1TSHRHDAC4 | |
| SCHEMBL6386162 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BHDAC1TSHRHDAC4 | |
| SCHEMBL6386168 | 0.86 | ITGB3 (0.55) | ITGB3ITGA2BHDAC1TSHRHDAC4 | |
| SCHEMBL6809194 | 0.86 | TSHR (0.41) | ITGB3ITGA2BTSHRCTSK | |
| SCHEMBL6809191 | 0.84 | ITGB3 (0.46) | ITGB3ITGA2BHDAC1TSHRHDAC8 | |
| SCHEMBL6809187 | 0.84 | ITGB3 (0.46) | ITGB3ITGA2BHDAC1TSHRHDAC8 | |
| SCHEMBL24485007 | 0.84 | HRH2 (0.43) | ITGB3ITGA2BTSHRCTSKHDAC8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | FERRING B.V. | 2008-10-16 | — | — | US | disclosed |
| US-7335677-B2 | Inhibitors of dipeptidyl peptidase IV | FERRING B.V. (NL) | 2008-02-26 | — | — | US | disclosed |
| WO-2005019168-A2 | FLUORINATED LYSINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | PFIZER PRODUCTS INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | FERRING B. V. | 2005-02-24 | — | — | US | disclosed |
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
| US-20040235752-A1 | 3-fluoro-pyrrolidines as antidiabetic agents | FERRING B.V. (NL) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043292-A1 | Fluorinated lysine derivatives as dipeptidyl peptidase IV inhibitors | DPP4, DPP7, ALPI | ITGB3 335/4885ITGA2B 660/4885HDAC1 234/4885 |
| US-20040235752-A1 | 3-fluoro-pyrrolidines as antidiabetic agents | DPP4, DPP7, DPP3 | ITGB3 3366/4885ITGA2B 4014/4885HDAC1 513/4885 |
| US-20050043299-A1 | Inhibitors of dipeptidyl peptidase iv | DPP4, DPP9, DPP3 | ITGB3 4014/4885ITGA2B 3782/4885HDAC1 1050/4885 |
| US-20080255126-A1 | Inhibitors of post-proline cleaving proteases | PREP, PEPD, DPP4 | ITGB3 4250/4885ITGA2B 4214/4885HDAC1 854/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.